

Tuberculosis profile: Indonesia

Population 2021: 274 million

Estimates of TB burden*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	969 000 (872 000-1 070 000)	354 (318-391)
HIV-positive TB incidence	22 000 (9 600-40 000)	8.1 (3.5-14)
MDR/RR-TB incidence**	28 000 (15 000-41 000)	10 (5.5-15)
HIV-negative TB mortality	144 000 (126 000-162 000)	52 (46-59)
HIV-positive TB mortality	6 500 (5 700-7 300)	2.4 (2.1-2.7)

Estimated proportion of TB cases with MDR/RR-TB*, 2021

New cases	2.2% (1.3-3.5)
Previously treated cases	25% (24-26)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2021	45% (40-50)
TB patients facing catastrophic total costs, 2020	38% (33-44)
TB case fatality ratio (estimated mortality/estimated incidence), 2021	16% (13-18)

TB case notifications, 2021

Total new and relapse	432 577
- % tested with rapid diagnostics at time of diagnosis	50%
- % with known HIV status	48%
- % pulmonary	92%
- % bacteriologically confirmed ^	56%
- % children aged 0-14 years	9%
- % women (aged ≥15 years)	38%
- % men (aged ≥15 years)	53%
Total cases notified	443 235

TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	8 015	3.8%
- on antiretroviral therapy	3 242	40%

Drug-resistant TB care**, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	73%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	94%
Laboratory-confirmed cases - MDR/RR-TB ^^	8 268
Patients started on treatment - MDR/RR-TB ^^	5 234
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	392
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	417
MDR/RR-TB cases tested for resistance to any fluoroquinolone	3 780

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	86%	362 523
Previously treated cases, excluding relapse, registered in 2020	80%	8 441
HIV-positive TB cases registered in 2020	68%	7 996
MDR/RR-TB cases started on second-line treatment in 2019	47%	5 276
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019	32%	351


TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	4.6%
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	3.7% (3.4-4)


Funding for TB

Funding for TB, 2021 (US\$ millions)	172
- % domestic funding	54%
- % international funding	46%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




HIV-negative TB mortality (Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2021



Cases attributable to five risk factors, 2021



Funding for TB



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
** RR is TB resistant to rifampicin (R), MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
^ Calculated for pulmonary cases only
^^ Includes cases with unknown previous TB treatment history
^^^ Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed

Generated 2022-11-28 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)